Cambridge RNA startup raises $45M to break into CNS, liver disease

Five-year-old Cambridge startup Camp4 Therapeutics has quietly spent the last few years developing new, early-stage treatments centered around RNA. Now it’s got a fresh round of $45M in venture capital to take its lead compounds into the clinic.